Tendler Craig 4

What Happened

• Craig Tendler, a director of TuHURA Biosciences, was granted 156,240 derivative securities (an option award) on February 12, 2026. The reported acquisition price is $0.00, indicating a grant of options rather than a market purchase or exercise. The filing was submitted on Feb 17, 2026 and is timely under Form 4 rules.
• This is an equity compensation award (not a sale or exercise), so there was no immediate cash paid or shares sold.

Key Details

• Transaction date: 2026-02-12; Filing date: 2026-02-17 (timely).
• Transaction type/code: A = Award/Grant (derivative securities); reported price = $0.00.
• Amount granted: 156,240 options (derivative securities). Total value at grant not reported in the Form 4.
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1: The grant represents an annual option under the TuHURA 2024 Equity Incentive Plan. One‑third of these options vest on each of the first, second and third anniversaries of Feb 12, 2026.
  • F2: The filing also references a previously granted annual option (March 10, 2025) that vests one‑third on each anniversary of March 10, 2025.
• No 10b5-1 plan, tax withholding, cashless exercise, or late-filing flags were reported.

Context

• This is a compensation grant to a director (common corporate practice) rather than an insider purchase or sale. Such awards are intended to align executives/directors with long‑term shareholder value but do not necessarily signal near‑term trading intentions.
• Because these are option grants (derivatives) with multi‑year vesting, the securities are not exercisable immediately in full and were not sold; they simply increase potential future equity if vested and exercised.